Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Cancer Res

Retrieve available abstracts of 177 articles:
HTML format

Single Articles

    May 2024
  1. LIU D, Wei B, Liang L, Sheng Y, et al
    The Circadian Clock Component RORA Increases Immunosurveillance in Melanoma by Inhibiting PD-L1 Expression.
    Cancer Res. 2024 May 8. doi: 10.1158/0008-5472.CAN-23-3942.
    PubMed     Abstract available

    April 2024
  2. ZHENG SM, Feng YC, Zhu Q, Li RQ, et al
    MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer.
    Cancer Res. 2024 Apr 9:OF1-OF15. doi: 10.1158/0008-5472.CAN-23-3046.
    PubMed     Abstract available

    Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans.
    Cancer Res. 2024;84:953-955.
    PubMed     Abstract available

    February 2024
  4. YAMAMOTO T, Hayashida T, Masugi Y, Oshikawa K, et al
    PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer.
    Cancer Res. 2024 Feb 22. doi: 10.1158/0008-5472.CAN-23-2266.
    PubMed     Abstract available

  5. YAN L, Wu M, Wang T, Yuan H, et al
    Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming that Drives Immune Evasion.
    Cancer Res. 2024 Feb 9. doi: 10.1158/0008-5472.CAN-23-2390.
    PubMed     Abstract available

  6. BERNARD MJ, Goldstein AS
    A metabolic-epigenetic mechanism directs cell fate and therapeutic sensitivity in breast cancer.
    Cancer Res. 2024 Feb 8. doi: 10.1158/0008-5472.CAN-24-0460.
    PubMed     Abstract available

  7. GEDIK ME, Saatci O, Oberholtzer N, Uner M, et al
    Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer.
    Cancer Res. 2024 Feb 6. doi: 10.1158/0008-5472.CAN-23-2812.
    PubMed     Abstract available

    January 2024
  8. XU X, Bok I, Jasani N, Wang K, et al
    PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis.
    Cancer Res. 2024 Jan 9:OF1-OF17. doi: 10.1158/0008-5472.CAN-23-1730.
    PubMed     Abstract available

  9. MARQUEZ-PALENCIA M, Reza Herrera L, Parida PK, Ghosh S, et al
    AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer.
    Cancer Res. 2024 Jan 8. doi: 10.1158/0008-5472.CAN-23-1459.
    PubMed     Abstract available

  10. SOOSAINATHAN A, Iravani M, El-Botty R, Alexander J, et al
    Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
    Cancer Res. 2024;84:17-25.
    PubMed     Abstract available

    December 2023
  11. KIM S, Oh J, Park C, Kim M, et al
    FAM3C in cancer-associated adipocytes promotes breast cancer cell survival and metastasis.
    Cancer Res. 2023 Dec 20. doi: 10.1158/0008-5472.CAN-23-1641.
    PubMed     Abstract available

  12. LIN P, Lourenco C, Cruickshank J, Palomero L, et al
    Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality.
    Cancer Res. 2023;83:4015-4029.
    PubMed     Abstract available

  13. COMPTON ZT, Mallo D, Maley CC
    Stronger Together: Cancer Clones Cooperate to Alleviate Growth Barriers in Critical Cancer Progression Transitions.
    Cancer Res. 2023;83:4013-4014.
    PubMed     Abstract available

  14. MICHAUD DE, Guerriero JL
    Myeloid cells pave the metastatic road in breast cancer.
    Cancer Res. 2023 Dec 6. doi: 10.1158/0008-5472.CAN-23-3803.
    PubMed     Abstract available

  15. FAN H, Xu Z, Yao K, Zheng B, et al
    Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1443.
    PubMed     Abstract available

    November 2023
  16. TAO H, Jin C, Zhou L, Deng Z, et al
    PRMT1 inhibition activates the interferon pathway to potentiate antitumor immunity and enhance checkpoint blockade efficacy in melanoma.
    Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-1082.
    PubMed     Abstract available

  17. WALL SW, Echeverria GV
    Avoiding Extinction: Cancer-Associated Fibroblasts Help Triple-Negative Breast Cancer Outrun Chemotherapy.
    Cancer Res. 2023;83:3667-3669.
    PubMed     Abstract available

  18. XU Y, Li X, Zhang S, Tang M, et al
    CircMMP2(6,7) cooperates with beta-catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis.
    Cancer Res. 2023 Nov 14. doi: 10.1158/0008-5472.CAN-23-1899.
    PubMed     Abstract available

    October 2023
  19. AHN S, Park JH, Grimm SL, Piyarathna DWB, et al
    Metabolomic rewiring promotes endocrine therapy resistance in breast cancer.
    Cancer Res. 2023 Oct 31. doi: 10.1158/0008-5472.CAN-23-0184.
    PubMed     Abstract available

  20. JACOBS C, Shah S, Lu WC, Ray H, et al
    HSF1 inhibits antitumor immune activity in breast cancer by suppressing CCL5 to block CD8+ T cell recruitment.
    Cancer Res. 2023 Oct 27. doi: 10.1158/0008-5472.CAN-23-0902.
    PubMed     Abstract available

  21. MIROSHNYCHENKO D, Miti T, Kumar P, Miller A, et al
    Stroma-mediated breast cancer cell proliferation indirectly drives chemoresistance by accelerating tumor recovery between chemotherapy cycles.
    Cancer Res. 2023 Oct 4. doi: 10.1158/0008-5472.CAN-23-0398.
    PubMed     Abstract available

  22. WU J, Subbiah V
    RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
    Cancer Res. 2023;83:3159-3161.
    PubMed     Abstract available

  23. WINGATE HF, Keyomarsi K
    Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All.
    Cancer Res. 2023;83:3165-3167.
    PubMed     Abstract available

  24. NAVARRO-YEPES J, Kettner NM, Rao X, Bishop CS, et al
    Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
    Cancer Res. 2023;83:3264-3283.
    PubMed     Abstract available

    September 2023
  25. FERRETTI LP, Bohi F, Leslie Pedrioli DM, Cheng PF, et al
    Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma.
    Cancer Res. 2023 Sep 20. doi: 10.1158/0008-5472.CAN-23-0485.
    PubMed     Abstract available

  26. LAWSON M, Cureton N, Ros S, Cheraghchi-Bashi-Astaneh A, et al
    The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance.
    Cancer Res. 2023 Sep 19. doi: 10.1158/0008-5472.CAN-23-0694.
    PubMed     Abstract available

  27. SHI J, Jiao T, Guo Q, Weng W, et al
    A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma.
    Cancer Res. 2023 Sep 5. doi: 10.1158/0008-5472.CAN-23-1356.
    PubMed     Abstract available

  28. MUKHERJEE D, Previs RA, Haines C, Al Abo M, et al
    Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
    Cancer Res. 2023;83:2889-2907.
    PubMed     Abstract available

    August 2023
  29. ZHU YY, Song L, Zhang YQ, Liu WL, et al
    Development of a rare earth nanoprobe enables in vivo real-time detection of sentinel lymph node metastasis of breast cancer using NIR-IIb imaging.
    Cancer Res. 2023 Aug 4:CAN-22-3432. doi: 10.1158/0008-5472.CAN-22-3432.
    PubMed     Abstract available

  30. SCHMIT SL, Purrington K, Figueiredo JC
    Efforts to Grow Genomic Research in Ancestrally Diverse and Admixed Populations.
    Cancer Res. 2023;83:2443-2444.
    PubMed     Abstract available

  31. HU C, Nagaraj AB, Shimelis H, Montalban G, et al
    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Cancer Res. 2023;83:2557-2571.
    PubMed     Abstract available

  32. SHU X, Li J, Chan UI, Su SM, et al
    BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance.
    Cancer Res. 2023;83:2614-2633.
    PubMed     Abstract available

  33. DING YC, Song H, Adamson AW, Schmolze D, et al
    Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
    Cancer Res. 2023;83:2600-2613.
    PubMed     Abstract available

  34. MATHUR D, Liao C, Lin W, La Ferlita A, et al
    The ratio of key metabolic transcripts is a predictive biomarker of breast cancer metastasis to the lung.
    Cancer Res. 2023 Aug 1:CAN-23-0153. doi: 10.1158/0008-5472.CAN-23-0153.
    PubMed     Abstract available

    July 2023
  35. WANG Z, Zhang N, Zhang M, Jiang Y, et al
    GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner.
    Cancer Res. 2023 Jul 18:CAN-22-3471. doi: 10.1158/0008-5472.CAN-22-3471.
    PubMed     Abstract available

  36. HERMIDA-PRADO F, Xie Y, Sherman S, Nagy Z, et al
    Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer.
    Cancer Res. 2023 Jul 14:CAN-23-1711. doi: 10.1158/0008-5472.CAN-23-1711.
    PubMed     Abstract available

  37. ACETO N, Gvozdenovic A
    Metastasis Unleashed: Hyposialylation Empowers Chemo-Evasive Circulating Tumor Cell Clusters in Breast Cancer.
    Cancer Res. 2023 Jul 7:CAN-23-1978. doi: 10.1158/0008-5472.CAN-23-1978.
    PubMed     Abstract available

  38. NULL JL, Kim DJ, McCann JV, Pramoonjago P, et al
    Periostin+ Stromal Cells Guide Lymphovascular Invasion by Cancer Cells.
    Cancer Res. 2023;83:2105-2122.
    PubMed     Abstract available

  39. MARIN A, Mamun AA, Patel H, Akamatsu H, et al
    Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer.
    Cancer Res. 2023 Jul 5:CAN-22-3617. doi: 10.1158/0008-5472.CAN-22-3617.
    PubMed     Abstract available

    June 2023
  40. FATTORI S, Le Roy A, Houacine J, Robert L, et al
    CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.
    Cancer Res. 2023 Jun 28:CAN-23-0613. doi: 10.1158/0008-5472.CAN-23-0613.
    PubMed     Abstract available

  41. ADAKU N, Ostendorf BN, Mei W, Tavazoie SF, et al
    Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression.
    Cancer Res. 2023 Jun 19:CAN-23-1252. doi: 10.1158/0008-5472.CAN-23-1252.
    PubMed     Abstract available

  42. JAILKHANI N, Clauser KR, Mak HH, Rickelt S, et al
    Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases.
    Cancer Res. 2023;83:2052-2065.
    PubMed     Abstract available

  43. LI Z, Li T, Yates ME, Wu Y, et al
    The EstroGene database reveals diverse temporal, context-dependent, and bidirectional estrogen receptor regulomes in breast cancer.
    Cancer Res. 2023 Jun 5:CAN-23-0539. doi: 10.1158/0008-5472.CAN-23-0539.
    PubMed     Abstract available

  44. CHENG X, Sun Y, Highkin M, Vemalapally N, et al
    Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 -Cyclin D1 axis driving tumorigenesis and drug resistance.
    Cancer Res. 2023 Jun 5:CAN-22-3558. doi: 10.1158/0008-5472.CAN-22-3558.
    PubMed     Abstract available

    May 2023
  45. KIM D, An L, Moon J, Maymi VI, et al
    Ccr2+ monocyte-derived macrophages influence trajectories of acquired therapy resistance in Braf-mutant melanoma.
    Cancer Res. 2023 May 17:CAN-22-2841. doi: 10.1158/0008-5472.CAN-22-2841.
    PubMed     Abstract available

  46. PENG WT, Jin X, Xu XE, Yang YS, et al
    Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.
    Cancer Res. 2023 May 2:OF1-OF14. doi: 10.1158/0008-5472.CAN-22-2143.
    PubMed     Abstract available

    April 2023
  47. PARK HR, Shiva A, Cummings P, Kim S, et al
    Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma.
    Cancer Res. 2023 Apr 24:CAN-22-2838. doi: 10.1158/0008-5472.CAN-22-2838.
    PubMed     Abstract available

  48. GOU X, Kim BJ, Anurag M, Lei JT, et al
    Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer.
    Cancer Res. 2023 Apr 18:CAN-22-3484. doi: 10.1158/0008-5472.CAN-22-3484.
    PubMed     Abstract available

  49. SUN Z, Jiang Q, Gao B, Zhang X, et al
    AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis.
    Cancer Res. 2023;83:1264-1279.
    PubMed     Abstract available

  50. LU XX, Yang WX, Pei YC, Luo H, et al
    An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression.
    Cancer Res. 2023 Apr 14:CAN-22-0536. doi: 10.1158/0008-5472.CAN-22-0536.
    PubMed     Abstract available

    March 2023
  51. EICHHOFF OM, Stoffel CI, Kasler J, Briker L, et al
    ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
    Cancer Res. 2023 Mar 22:OF1-OF19. doi: 10.1158/0008-5472.CAN-22-1826.
    PubMed     Abstract available

    February 2023
  52. MALIK N, Kim YI, Yan H, Tseng YC, et al
    Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer.
    Cancer Res. 2023 Feb 14:CAN-22-2525. doi: 10.1158/0008-5472.CAN-22-2525.
    PubMed     Abstract available

    January 2023
  53. SUN Y, Li X, Yin C, Zhang J, et al
    AMPK phosphorylates ZDHHC13 to increase MC1R activity and suppress melanomagenesis.
    Cancer Res. 2023 Jan 26:CAN-22-2595. doi: 10.1158/0008-5472.CAN-22-2595.
    PubMed     Abstract available

  54. ANSTINE LJ, Majmudar PR, Aponte A, Singh S, et al
    TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis.
    Cancer Res. 2023 Jan 25:CAN-22-3133. doi: 10.1158/0008-5472.CAN-22-3133.
    PubMed     Abstract available

  55. LLANO E, Todeschini AL, Felipe-Medina N, Corte-Torres MD, et al
    The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors.
    Cancer Res. 2023;83:239-250.
    PubMed     Abstract available

  56. DAS C, Adhikari S, Bhattacharya A, Chakraborty S, et al
    Epigenetic-Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer.
    Cancer Res. 2023 Jan 18:CAN-22-3015. doi: 10.1158/0008-5472.CAN-22-3015.
    PubMed     Abstract available

    December 2022
  57. LIAO L, Zhang YL, Deng L, Chen C, et al
    Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer.
    Cancer Res. 2022 Dec 9:CAN-22-2709. doi: 10.1158/0008-5472.CAN-22-2709.
    PubMed     Abstract available

  58. WEI L, Gao H, Yu J, Zhang H, et al
    Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer.
    Cancer Res. 2022 Dec 5:CAN-22-1016. doi: 10.1158/0008-5472.CAN-22-1016.
    PubMed     Abstract available

    November 2022
  59. ABECUNAS C, Whitehead CE, Ziemke EK, Baumann DG, et al
    Loss of NF1 in melanoma confers sensitivity to SYK kinase inhibition.
    Cancer Res. 2022 Nov 21:CAN-22-0883. doi: 10.1158/0008-5472.CAN-22-0883.
    PubMed     Abstract available

  60. STEVENS LE, Peluffo G, Qiu X, Temko D, et al
    JAK-STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states.
    Cancer Res. 2022 Nov 21:CAN-22-0423. doi: 10.1158/0008-5472.CAN-22-0423.
    PubMed     Abstract available

  61. WANG F, Moon W, Letsou W, Sapkota Y, et al
    Genome-wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk.
    Cancer Res. 2022 Nov 10. pii: 710536. doi: 10.1158/0008-5472.CAN-22-1888.
    PubMed     Abstract available

  62. GONG P, Chin SL, Allen WM, Ballal H, et al
    Quantitative Micro-Elastography Enables In Vivo Detection of Residual Cancer in the Surgical Cavity during Breast-Conserving Surgery.
    Cancer Res. 2022;82:4093-4104.
    PubMed     Abstract available

  63. PERRONE M, Chiodoni C, Lecchi M, Botti L, et al
    ATF3 reprograms the bone marrow niche in response to early breast cancer transformation.
    Cancer Res. 2022 Nov 1. pii: 710151. doi: 10.1158/0008-5472.CAN-22-0651.
    PubMed     Abstract available

    October 2022
  64. HALPERIN C, Hey J, Weichenhan D, Stein Y, et al
    Global DNA Methylation Analysis of Cancer-Associated Fibroblasts Reveals Extensive Epigenetic Rewiring Linked with RUNX1 Upregulation in Breast Cancer Stroma.
    Cancer Res. 2022 Oct 26:OF1-OF14. doi: 10.1158/0008-5472.CAN-22-0209.
    PubMed     Abstract available

  65. BASSIOUNI R, Idowu MO, Gibbs LD, Robila V, et al
    Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer.
    Cancer Res. 2022 Oct 25. pii: 710045. doi: 10.1158/0008-5472.CAN-22-2682.
    PubMed     Abstract available

  66. HARGROVE-WILEY E, Fingleton B
    Sex hormones in breast cancer immunity.
    Cancer Res. 2022 Oct 24. pii: 709945. doi: 10.1158/0008-5472.CAN-22-1829.
    PubMed     Abstract available

  67. TARANTINO P, Tolaney SM
    The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.
    Cancer Res. 2022;82:3659-3661.
    PubMed     Abstract available

  68. BLAWSKI R, Toska E
    A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
    Cancer Res. 2022;82:3668-3670.
    PubMed     Abstract available

  69. DURO-SANCHEZ S, Nadal-Serrano M, Lalinde-Gutierrez M, Arenas EJ, et al
    Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709715. doi: 10.1158/0008-5472.CAN-22-0787.
    PubMed     Abstract available

  70. HONG J, Lee JH, Zhang Z, Wu Y, et al
    PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709714. doi: 10.1158/0008-5472.CAN-22-0736.
    PubMed     Abstract available

  71. GAMBI G, Mengus G, Davidson G, Demesmaeker E, et al
    The lncRNA LENOX interacts with RAP2C to regulate metabolism and promote resistance to MAPK inhibition in melanoma.
    Cancer Res. 2022 Oct 10. pii: 709677. doi: 10.1158/0008-5472.CAN-22-0959.
    PubMed     Abstract available

  72. ELKHOLI IE, Lalonde A, Park M, Cote JF, et al
    Breast Cancer Metastatic Dormancy and Relapse: An enigma of microenvironment(s).
    Cancer Res. 2022 Oct 10. pii: 709673. doi: 10.1158/0008-5472.CAN-22-1902.
    PubMed     Abstract available

    September 2022
  73. TOKURA M, Nakayama J, Prieto-Vila M, Shiino S, et al
    Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.
    Cancer Res. 2022;82:3236-3248.
    PubMed     Abstract available

  74. SMALLEY I, Smalley KSM
    Space Is the Place: Mapping the Cell-Cell Interactions That Predict Immunotherapy Responses in Melanoma.
    Cancer Res. 2022;82:3198-3200.
    PubMed     Abstract available

  75. LIU H, Lyu H, Jiang G, Chen D, et al
    ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer.
    Cancer Res. 2022 Sep 7. pii: 709106. doi: 10.1158/0008-5472.CAN-22-0800.
    PubMed     Abstract available

  76. XU X, Wang K, Vera O, Verma A, et al
    Gain of Chromosome 1q Perturbs a Competitive Endogenous RNA Network to Promote Melanoma Metastasis.
    Cancer Res. 2022;82:3016-3031.
    PubMed     Abstract available

  77. SRIVASTAVA A, Tommasi C, Sessions D, Mah A, et al
    MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET.
    Cancer Res. 2022;82:3143-3157.
    PubMed     Abstract available

    August 2022
  78. XU X, Wang K, Vera O, Verma A, et al
    Gain of chromosome 1q perturbs a competitive endogenous RNA network to promote melanoma metastasis.
    Cancer Res. 2022 Aug 31. pii: 706990. doi: 10.1158/0008-5472.CAN-22-0283.
    PubMed     Abstract available

  79. GUO Q, Wang H, Duan J, Luo W, et al
    An alternatively spliced p62 isoform confers resistance to chemotherapy in breast cancer.
    Cancer Res. 2022 Aug 29. pii: 708925. doi: 10.1158/0008-5472.CAN-22-0909.
    PubMed     Abstract available

  80. NANDI A, Debnath R, Nayak A, To TKJ, et al
    Dll1-mediated Notch signaling drives tumor cell crosstalk with cancer associated fibroblasts to promote radioresistance in breast cancer.
    Cancer Res. 2022 Aug 24. pii: 708708. doi: 10.1158/0008-5472.CAN-21-1225.
    PubMed     Abstract available

  81. SCHATTON T, Itoh Y, Martins C, Rasbach E, et al
    Inhibition of melanoma cell-intrinsic Tim-3 stimulates MAPK-dependent tumorigenesis.
    Cancer Res. 2022 Aug 18. pii: 708039. doi: 10.1158/0008-5472.CAN-22-0970.
    PubMed     Abstract available

  82. ZENG E, He W, Sjolander A, Bergqvist J, et al
    Determinants and effectiveness of extending the duration of adjuvant hormone therapy beyond 5 years in breast cancer patients.
    Cancer Res. 2022 Aug 18. pii: 708038. doi: 10.1158/0008-5472.CAN-22-0900.
    PubMed     Abstract available

    Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
    Cancer Res. 2022;82:2811-2820.
    PubMed     Abstract available

  84. ALTWEGG KA, Viswanadhapalli S, Mann M, Chakravarty D, et al
    A first-in-class inhibitor of ER coregulator PELP1 targets ER+ breast cancer.
    Cancer Res. 2022 Aug 11. pii: 707658. doi: 10.1158/0008-5472.CAN-22-0698.
    PubMed     Abstract available

  85. NARDONE A, Qiu X, Spisak S, Nagy Z, et al
    A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
    Cancer Res. 2022 Aug 11. pii: 707656. doi: 10.1158/0008-5472.CAN-21-3186.
    PubMed     Abstract available

  86. WU C, Jarrett AM, Zhou Z, Elshafeey N, et al
    MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer.
    Cancer Res. 2022 Aug 1. pii: 707362. doi: 10.1158/0008-5472.CAN-22-1329.
    PubMed     Abstract available

    July 2022
  87. TIMPERI E, Gueguen P, Molgora M, Magagna I, et al
    Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer.
    Cancer Res. 2022 Jul 21. pii: 707127. doi: 10.1158/0008-5472.CAN-22-1427.
    PubMed     Abstract available

  88. ANTORANZ A, Van Herck Y, Bolognesi MM, Lynch SM, et al
    Mapping the immune landscape in metastatic melanoma reveals localized cell-cell interactions that predict immunotherapy response.
    Cancer Res. 2022 Jul 14. pii: 707010. doi: 10.1158/0008-5472.CAN-22-0363.
    PubMed     Abstract available

  89. CHEN F, Park SL, Wilkens LR, Wan P, et al
    Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
    Cancer Res. 2022 Jul 14. pii: 707009. doi: 10.1158/0008-5472.CAN-21-4461.
    PubMed     Abstract available

    June 2022
  90. KALRA R, Chen CH, Wang J, Salam AB, et al
    Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer.
    Cancer Res. 2022 Jun 23. pii: 705013. doi: 10.1158/0008-5472.CAN-21-3106.
    PubMed     Abstract available

  91. CLARIDGE SE, Hopkins BD
    PI3King the Environment for Growth: PI3K Activation Drives Transcriptome Changes That Support Oncogenic Growth.
    Cancer Res. 2022;82:2216-2218.
    PubMed     Abstract available

  92. LADEWIG E, Michelini F, Jhaveri K, Castel P, et al
    The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
    Cancer Res. 2022;82:2269-2280.
    PubMed     Abstract available

  93. ZHANG Z, Golomb L, Meyerson M
    Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
    Cancer Res. 2022;82:2171-2184.
    PubMed     Abstract available

  94. CAI W, Nguyen MQ, Wilski NA, Purwin TJ, et al
    A Genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1/2 inhibitors in NRAS mutant melanoma.
    Cancer Res. 2022 Jun 3. pii: 699338. doi: 10.1158/0008-5472.CAN-21-3217.
    PubMed     Abstract available

    May 2022
  95. BONFILL-TEIXIDOR E, Iurlaro R, Handl C, Wichmann J, et al
    Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis.
    Cancer Res. 2022 May 18. pii: 699020. doi: 10.1158/0008-5472.CAN-21-4152.
    PubMed     Abstract available

  96. KOPANJA D, Chand V, O'Brien EM, Mukhopadhyay NK, et al
    Transcriptional repression by FoxM1 suppresses tumor differentiation and promotes metastasis of breast cancer.
    Cancer Res. 2022 May 18. pii: 699021. doi: 10.1158/0008-5472.CAN-22-0410.
    PubMed     Abstract available

  97. WEI YT, Wang XR, Yan C, Huang F, et al
    Thymosin alpha-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis.
    Cancer Res. 2022;82:1991-2002.
    PubMed     Abstract available

  98. FATHERREE JP, Guarin JR, McGinn RA, Naber SP, et al
    Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase.
    Cancer Res. 2022;82:2031-2044.
    PubMed     Abstract available

  99. ROVERA C, Berestjuk I, Lecacheur M, Tavernier C, et al
    Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3-Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells.
    Cancer Res. 2022;82:1774-1788.
    PubMed     Abstract available

  100. MARCZYK M, Gunasekharan V, Casadevall D, Qing T, et al
    Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.
    Cancer Res. 2022;82:1698-1711.
    PubMed     Abstract available

  101. ISKANDER K, Paquet M, Brayton C, Jaiswal AK, et al
    Editor's Note: Deficiency of NRH: Quinone Oxidoreductase 2 Increases Susceptibility to 7,12-Dimethylbenz(a)anthracene and Benzo(a)pyrene-Induced Skin Carcinogenesis.
    Cancer Res. 2022;82:1845.

  102. LUND AW
    Be Easy and Chill: Melanoma Cells Tell Lymph Node Fibroblasts to Relax.
    Cancer Res. 2022;82:1692-1694.
    PubMed     Abstract available

    April 2022
  103. RODRIGUEZ-TIRADO C, Kale N, Carlini MJ, Shrivastava N, et al
    NR2F1 is a barrier to dissemination of early stage breast cancer cells.
    Cancer Res. 2022 Apr 26. pii: 694636. doi: 10.1158/0008-5472.CAN-21-4145.
    PubMed     Abstract available

  104. SINGH S, Lee N, Pedroza DA, Bado IL, et al
    Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer.
    Cancer Res. 2022 Apr 20. pii: 694629. doi: 10.1158/0008-5472.CAN-21-3714.
    PubMed     Abstract available

  105. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    PubMed     Abstract available

  106. QUIROS-GONZALEZ I, Tomaszewski MR, Golinska MA, Brown E, et al
    Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.
    Cancer Res. 2022;82:1658-1668.
    PubMed     Abstract available

  107. WANG H, Xu H, Chen W, Cheng M, et al
    Rab13 sustains breast cancer stem cells by supporting tumor-stroma crosstalk.
    Cancer Res. 2022 Apr 8. pii: 694330. doi: 10.1158/0008-5472.CAN-21-4097.
    PubMed     Abstract available

  108. ELWAKEEL E, Bruggemann M, Wagih J, Lityagina O, et al
    Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis.
    Cancer Res. 2022;82:1380-1395.
    PubMed     Abstract available

  109. HONG Z, Liu T, Wan L, Fa P, et al
    Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy.
    Cancer Res. 2022;82:1298-1312.
    PubMed     Abstract available

    March 2022
  110. WILSON Z, Odedra R, Wallez Y, Wijnhoven PWG, et al
    ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Cancer Res. 2022;82:1140-1152.
    PubMed     Abstract available

    February 2022
  111. BHATIA S, Kramer M, Russo S, Naik P, et al
    Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor-intrinsic characteristics.
    Cancer Res. 2022 Feb 18. pii: 681619. doi: 10.1158/0008-5472.CAN-21-2807.
    PubMed     Abstract available

  112. SCHEIDMANN MC, Castro-Giner F, Strittmatter K, Krol I, et al
    An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression.
    Cancer Res. 2022;82:681-694.
    PubMed     Abstract available

  113. LIAO C, Glodowski CR, Fan C, Liu J, et al
    Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
    Cancer Res. 2022;82:665-680.
    PubMed     Abstract available

  114. BOONEN RACM, Wiegant WW, Celosse N, Vroling B, et al
    Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Cancer Res. 2022;82:615-631.
    PubMed     Abstract available

  115. GILL JG, Leef SN, Ramesh V, Martin-Sandoval MS, et al
    A short isoform of spermatogenic enzyme GAPDHS functions as a metabolic switch and limits metastasis in melanoma.
    Cancer Res. 2022 Feb 11. pii: 0008-5472.CAN-21-2062.
    PubMed     Abstract available

  116. LI XQ, Zhang R, Lu H, Yue XM, et al
    Extracellular vesicle-packaged CDH11 and ITGA5 induce the premetastatic niche for bone colonization of breast cancer cells.
    Cancer Res. 2022 Feb 11. pii: 0008-5472.CAN-21-1331.
    PubMed     Abstract available

    January 2022
  117. LI Z, Wu Y, Yates ME, Tasdemir N, et al
    Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis.
    Cancer Res. 2022 Jan 25. pii: 0008-5472.CAN-21-2576.
    PubMed     Abstract available

  118. LIU T, Zhou L, Xiao Y, Andl T, et al
    BRAF Inhibitors Reprogram Cancer-Associated Fibroblasts to Drive Matrix Remodeling and Therapeutic Escape in Melanoma.
    Cancer Res. 2022 Jan 21. pii: 0008-5472.CAN-21-0614.
    PubMed     Abstract available

  119. MAJORINI MT, Colombo MP, Lecis D
    Few, but efficient: the role of mast cells in breast cancer and other solid tumors.
    Cancer Res. 2022 Jan 19. pii: 0008-5472.CAN-21-3424.
    PubMed     Abstract available

  120. HAJ-SHOMALY J, Vorontsova A, Barenholz-Cohen T, Levi-Galibov O, et al
    T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy.
    Cancer Res. 2022;82:278-291.
    PubMed     Abstract available

  121. ZHU WJ, Chen X, Guo XY, Liu HT, et al
    Low glucose-induced overexpression of HOXC-AS3 promotes metabolic reprogramming of breast cancer.
    Cancer Res. 2022 Jan 14. pii: 0008-5472.CAN-21-1179.
    PubMed     Abstract available

    December 2021
  122. XU Y, Ren W, Li Q, Duan C, et al
    LncRNA Uc003xsl.1-mediated activation of the NF-kappaB/IL8 axis promotes progression of triple-negative breast cancer.
    Cancer Res. 2021 Dec 29. pii: 0008-5472.CAN-21-1446.
    PubMed     Abstract available

  123. BEETHAM H, Griffith BGC, Murina O, Loftus AE, et al
    Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-21-0373.
    PubMed     Abstract available

  124. OBA T, Kajihara R, Yokoi T, Repasky EA, et al
    Neoadjuvant In Situ Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors.
    Cancer Res. 2021;81:6183-6195.
    PubMed     Abstract available

  125. MOORE J, Ma L, Lazar A, Barcellos-Hoff MH, et al
    Mammary tumor-derived transplants as breast cancer models to evaluate tumor-immune interactions and therapeutic responses.
    Cancer Res. 2021 Dec 13. pii: 0008-5472.CAN-21-0253.
    PubMed     Abstract available

    November 2021
  126. CHOI SR, Hwang CY, Lee J, Cho KH, et al
    Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability.
    Cancer Res. 2021 Nov 29. pii: 0008-5472.CAN-21-0621.
    PubMed     Abstract available

  127. LIU W, Stachura P, Xu HC, Varaljai R, et al
    BAFF attenuates immunosuppressive monocytes in the melanoma tumor microenvironment.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-1171.
    PubMed     Abstract available

  128. YUAN H, Yan L, Wu M, Shang Y, et al
    Analysis of the estrogen receptor-associated lncRNA landscape identifies a role for ERLC1 in breast cancer progression.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-1155.
    PubMed     Abstract available

  129. TUBITA A, Lombardi Z, Tusa I, Lazzeretti A, et al
    Inhibition of ERK5 elicits cellular senescence in melanoma via the cyclin-dependent kinase inhibitor p21.
    Cancer Res. 2021 Nov 19. pii: 0008-5472.CAN-21-0993.
    PubMed     Abstract available

  130. SUBRAMANIAN S, Daquinag AC, AghaAmiri S, Ghosh SC, et al
    Characterization of Peptides Targeting Metastatic Tumor Cells as Probes for Cancer Detection and Vehicles for Therapy Delivery.
    Cancer Res. 2021;81:5756-5764.
    PubMed     Abstract available

  131. JANJANAM J, Pano G, Wang R, Minden-Birkenmaier BA, et al
    Matricellular Protein WISP2 Is an Endogenous Inhibitor of Collagen Linearization and Cancer Metastasis.
    Cancer Res. 2021;81:5666-5677.
    PubMed     Abstract available

  132. YOKOYAMA S, Takahashi A, Kikuchi R, Nishibu S, et al
    SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 axis.
    Cancer Res. 2021 Nov 2. pii: 0008-5472.CAN-21-2078.
    PubMed     Abstract available

  133. DAMODARAN S, Hortobagyi GN
    Estrogen Receptor: A Paradigm for Targeted Therapy.
    Cancer Res. 2021;81:5396-5398.
    PubMed     Abstract available

  134. GRISARU-TAL S, Dulberg S, Beck L, Zhang C, et al
    Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity.
    Cancer Res. 2021;81:5555-5571.
    PubMed     Abstract available

  135. TEMPS C, Lietha D, Webb ER, Li XF, et al
    A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.
    Cancer Res. 2021;81:5438-5450.
    PubMed     Abstract available

  136. HINSHAW DC, Hanna A, Lama-Sherpa T, Metge B, et al
    Hedgehog Signaling Regulates Metabolism and Polarization of Mammary Tumor-Associated Macrophages.
    Cancer Res. 2021;81:5425-5437.
    PubMed     Abstract available

    October 2021
  137. DONE SJ, Kanwar N, Balde Z, Nair R, et al
    Heterogeneity of circulating tumor cell-associated genomic gains in breast cancer and its association with the host immune response.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1079.
    PubMed     Abstract available

  138. GOU X, Anurag M, Lei JT, Kim BJ, et al
    Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1256.
    PubMed     Abstract available

  139. PATEL A, Garcia-Closas M, Olshan AF, Perou CM, et al
    Gene level germline contributions to clinical risk of recurrence scores in Black and White breast cancer patients.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1207.
    PubMed     Abstract available

  140. AGUIRRE-PORTOLES C, Payne R, Trautz A, Foskett JK, et al
    ZIP9 is a Druggable Determinant of Sex Differences in Melanoma.
    Cancer Res. 2021 Oct 27. pii: 0008-5472.CAN-21-0982.
    PubMed     Abstract available

  141. HUGGINS DN, LaRue RS, Wang Y, Knutson TP, et al
    Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset.
    Cancer Res. 2021;81:5284-5295.
    PubMed     Abstract available

  142. SALTARI A, Dzung A, Quadri M, Tiso N, et al
    Specific activation of the CD271 intracellular domain in combination with chemotherapy or targeted therapy inhibits melanoma progression.
    Cancer Res. 2021 Oct 13. pii: 0008-5472.CAN-21-0117.
    PubMed     Abstract available

  143. VALENCIA JC, Erwin-Cohen RA, Clavijo PE, Allen C, et al
    Myeloid derived suppressive cell expansion promotes melanoma growth and severity of autoimmunity by inhibiting CD40/IL-27 regulation in macrophages.
    Cancer Res. 2021 Oct 12. pii: 0008-5472.CAN-21-1148.
    PubMed     Abstract available

  144. WOITEK R, McLean MA, Ursprung S, Rueda OM, et al
    Hyperpolarized carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients.
    Cancer Res. 2021 Oct 8. pii: 0008-5472.CAN-21-1499.
    PubMed     Abstract available

    September 2021
  145. LIU C, Qiang J, Deng Q, Xia J, et al
    ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression.
    Cancer Res. 2021 Sep 27. pii: 0008-5472.CAN-21-1337.
    PubMed     Abstract available

  146. ZHAO X, Li J, Liu Z, Powers S, et al
    Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-2555.
    PubMed     Abstract available

  147. ANSARI KI, Bhan A, Saotome M, Tyagi A, et al
    Autocrine GMCSF Signaling Contributes to Growth of HER2(+) Breast Leptomeningeal Carcinomatosis.
    Cancer Res. 2021;81:4723-4735.
    PubMed     Abstract available

  148. EVANS KW, Yuca E, Scott SS, Zhao M, et al
    Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple negative breast cancer.
    Cancer Res. 2021 Sep 13. pii: 0008-5472.CAN-20-3242.
    PubMed     Abstract available

  149. FAURE C, Djerbi-Bouillie R, Domingot A, Bouzinba-Segard H, et al
    Allosteric inhibition of HER2 by Moesin-mimicking compounds targets HER2-positive cancers and brain metastases.
    Cancer Res. 2021 Sep 7. pii: 0008-5472.CAN-21-0162.
    PubMed     Abstract available

    August 2021
  150. ZUO H, Yang D, Wan Y
    Fam20C regulates bone resorption and breast cancer bone metastasis through osteopontin and BMP4.
    Cancer Res. 2021 Aug 25. pii: 0008-5472.CAN-20-3328.
    PubMed     Abstract available

  151. YU TJ, Liu YY, Li XG, Lian B, et al
    PDSS1-mediated activation of CAMK2A-STAT3 signaling promotes metastasis in triple-negative breast cancer.
    Cancer Res. 2021 Aug 18. pii: 0008-5472.CAN-21-0747.
    PubMed     Abstract available

  152. AHIRWAR DK, Charan M, Mishra S, Verma AK, et al
    Slit2 inhibits breast cancer metastasis by activating M1-like phagocytic and anti-fibrotic macrophages.
    Cancer Res. 2021 Aug 16. pii: 0008-5472.CAN-20-3909.
    PubMed     Abstract available

  153. PULEO J, Polyak K
    The MCF10 Model of Breast Tumor Progression.
    Cancer Res. 2021;81:4183-4185.
    PubMed     Abstract available

  154. APOSTOLIDI M, Vathiotis IA, Muthusamy V, Gaule P, et al
    Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
    Cancer Res. 2021;81:4346-4359.
    PubMed     Abstract available

  155. TANG K, Zhu L, Chen J, Wang D, et al
    Hypoxia promotes breast cancer cell growth by activating a glycogen metabolic program.
    Cancer Res. 2021 Aug 4. pii: 0008-5472.CAN-21-0753.
    PubMed     Abstract available

  156. WANG Y, Kartasalo K, Weitz P, Acs B, et al
    Predicting molecular phenotypes from histopathology images: a transcriptome-wide expression-morphology analysis in breast cancer.
    Cancer Res. 2021 Aug 2. pii: 0008-5472.CAN-21-0482.
    PubMed     Abstract available

    July 2021
  157. GOMEZ TEJEDA ZANUDO J, Mao P, Alcon C, Kowalski K, et al
    Cell line-specific network models of ER+ breast cancer identify potential PI3Kalpha inhibitor resistance mechanisms and drug combinations.
    Cancer Res. 2021 Jul 13. pii: 0008-5472.CAN-21-1208.
    PubMed     Abstract available

  158. TAKAYAMA KI, Honma T, Suzuki T, Kondoh Y, et al
    Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth.
    Cancer Res. 2021;81:3495-3508.
    PubMed     Abstract available

  159. STEINER MC, Marston JL, Iniguez LP, Bendall ML, et al
    Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
    Cancer Res. 2021;81:3449-3460.
    PubMed     Abstract available

  160. CHOI H, Kwon J, Cho MS, Sun Y, et al
    Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response.
    Cancer Res. 2021;81:3607-3620.
    PubMed     Abstract available

  161. YOO KH, Tang JJ, Rashid MA, Cho CH, et al
    Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments.
    Cancer Res. 2021;81:3727-3737.
    PubMed     Abstract available

    June 2021
  162. LAINE A, Nagelli SG, Farrington C, Butt U, et al
    CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis.
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-3651.
    PubMed     Abstract available

  163. CANO A, Lopez-Menendez C, Vazquez-Naharro A, Santos V, et al
    E2A modulates stemness, metastasis, and therapeutic resistance of breast cancer.
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-2685.
    PubMed     Abstract available

  164. SHARIF GM, Campbell MJ, Nasir A, Sengupta S, et al
    An AIB1 isoform alters enhancer access and enables progression of early stage triple-negative breast cancer.
    Cancer Res. 2021 Jun 16. pii: 0008-5472.CAN-20-3625.
    PubMed     Abstract available

  165. BHAN A, Ansari KI, Chen MY, Jandial R, et al
    Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2(+) Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression.
    Cancer Res. 2021;81:3200-3214.
    PubMed     Abstract available

  166. ZHOU Q, Howard ME, Tu X, Zhu Q, et al
    Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining.
    Cancer Res. 2021;81:3333-3346.
    PubMed     Abstract available

  167. HARRIS RJ, Cheung A, Ng JCF, Laddach R, et al
    Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes In Triple-Negative Breast Cancer.
    Cancer Res. 2021 Jun 15. pii: 0008-5472.CAN-20-3773.
    PubMed     Abstract available

  168. WANG T, Farvid MS, Kang JH, Holmes MD, et al
    Diabetes Risk Reduction Diet and Survival After Breast Cancer Diagnosis.
    Cancer Res. 2021 Jun 9. pii: 0008-5472.CAN-21-0256.
    PubMed     Abstract available

    May 2021
  169. YANG B, Li X, Fu Y, Guo E, et al
    MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
    Cancer Res. 2021;81:2714-2729.
    PubMed     Abstract available

  170. SHAN P, Yang F, Qi H, Hu Y, et al
    Alteration of MDM2 by the small molecule YF438 exerts anti-tumor effects in triple-negative breast cancer.
    Cancer Res. 2021 May 13. pii: 0008-5472.CAN-20-0922.
    PubMed     Abstract available

  171. HAPACH LA, Carey SP, Schwager SC, Taufalele PV, et al
    Phenotypic heterogeneity and metastasis of breast cancer cells.
    Cancer Res. 2021 May 11. pii: 0008-5472.CAN-20-1799.
    PubMed     Abstract available

  172. GUO Q, Bartish M, Goncalves C, Huang F, et al
    The MNK1/2-eIF4E axis supports immune suppression and metastasis in postpartum breast cancer.
    Cancer Res. 2021 May 11. pii: 0008-5472.CAN-20-3143.
    PubMed     Abstract available

    April 2021
  173. CHEN F, Chen Z, Guan T, Zhou Y, et al
    N6-methyladenosine regulates mRNA stability and translation efficiency of KRT7 to promote breast cancer lung metastasis.
    Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-3779.
    PubMed     Abstract available

    March 2021
  174. LI CI, Flanagan MR, Tang MC, Porter PL, et al
    Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma In Situ.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-20-4100.
    PubMed     Abstract available

  175. HU L, Su L, Cheng H, Mo C, et al
    Single-cell RNA sequencing reveals the cellular origin and evolution of breast cancer in BRCA1 mutation carriers.
    Cancer Res. 2021 Mar 16. pii: 0008-5472.CAN-20-2123.
    PubMed     Abstract available

    February 2021
  176. YU R, Longo J, van Leeuwen JE, Zhang C, et al
    Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching.
    Cancer Res. 2021 Feb 18. pii: 0008-5472.CAN-20-2642.
    PubMed     Abstract available

    January 2021
  177. XING F, Zhao D, Wu SY, Tyagi A, et al
    Epigenetic and post-transcriptional modulation of SOS1 can promote breast cancer metastasis through obesity-activated c-Met signaling in African American women.
    Cancer Res. 2021 Jan 14. pii: 0008-5472.CAN-19-4031.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.